CLINUVEL Pharmaceuticals
(ASX:CUV) has announced it's a step closer to making its drug SCENESSE, available to British patients who suffer from is a rare inherited metabolic disorder called EPP (Erythropoietic protoporphyria (EPP)).
It comes after the body responsible for providing evidence-based guidance to the National Health Service (NHS) in England, The National Institue of Health and Care Excellence (NICE) published a decision following an appeal hearing as part of an evaluation into CLINUVEL's drug SCENESSE.
The appeal hearing was requested by the company and three other consultee companies. It was held in London back in July.
One of the conclusion's from the appeal panel was that 'it was unreasonable for the committee to state that the trial results show small benefits with SCENESSE'.
Shares in Clinuvel Pharmaceuticals
(ASX:CUV) are trading 3.85 per cent lower at $18.75.
